Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2001 | 1 |
2003 | 1 |
2018 | 2 |
2019 | 3 |
2020 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Clin Pharmacol Drug Dev. 2019 May;8(4):480-491. doi: 10.1002/cpdd.628. Epub 2018 Nov 9.
Clin Pharmacol Drug Dev. 2019.
PMID: 30412360
Clinical Trial.
Translational Model-Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ-54175446, a P2X7 Receptor Antagonist.
Xu Y, Miao X, Ravenstijn P, Hijzen A, Schmidt ME, Nandy P, Zhou H.
Xu Y, et al. Among authors: hijzen a.
Clin Transl Sci. 2020 Mar;13(2):309-317. doi: 10.1111/cts.12711. Epub 2019 Nov 9.
Clin Transl Sci. 2020.
PMID: 31642608
Free PMC article.
Item in Clipboard
Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function.
Mertens N, Schmidt ME, Hijzen A, Van Weehaeghe D, Ravenstijn P, Depre M, de Hoon J, Van Laere K, Koole M.
Mertens N, et al. Among authors: hijzen a.
Sci Rep. 2021 Aug 9;11(1):16172. doi: 10.1038/s41598-021-95715-y.
Sci Rep. 2021.
PMID: 34373571
Free PMC article.
Item in Clipboard
18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446.
Koole M, Schmidt ME, Hijzen A, Ravenstijn P, Vandermeulen C, Van Weehaeghe D, Serdons K, Celen S, Bormans G, Ceusters M, Zhang W, Van Nueten L, Kolb H, de Hoon J, Van Laere K.
Koole M, et al. Among authors: hijzen a.
J Nucl Med. 2019 May;60(5):683-690. doi: 10.2967/jnumed.118.216747. Epub 2018 Sep 27.
J Nucl Med. 2019.
PMID: 30262518
Free article.
Item in Clipboard
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K.
Croucher PI, et al. Among authors: hijzen a.
Blood. 2001 Dec 15;98(13):3534-40. doi: 10.1182/blood.v98.13.3534.
Blood. 2001.
PMID: 11739154
Free article.
Item in Clipboard
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K.
Croucher PI, et al. Among authors: hijzen a.
J Bone Miner Res. 2003 Mar;18(3):482-92. doi: 10.1359/jbmr.2003.18.3.482.
J Bone Miner Res. 2003.
PMID: 12619933
Free article.
Item in Clipboard
Cite
Cite